A recent study published in the Journal of Affective Disorders reported that a more perplexing and enlightening psychedelic drug experience may be connected to a long-term decrease in anxiety and depression symptoms.

The researchers utilized machine learning to analyze the data of about 1,000 survey participants who were surveyed about their past non-clinical encounters with psychedelic drugs.

This study is the first to define different categories of subjective psychedelic experiences and connect them to outcomes related to mental health. The 985 participants provided information about the drugs they had used and answered questions about how mystical, insightful, or demanding their psychedelic experience had been. The survey measured outcomes such as depression and anxiety symptom levels and assessments of life satisfaction and psychological flexibility. This information may be helpful to practitioners as they assist patients in clinical trials examining the therapeutic potential of psychedelics.

The samples analyzed included participants using psilocybin, LSD, Ayahuasca, mescaline, peyote cactus, and 5-MeO-DMT, along with those who had used estimated dose levels of each drug individually. Three separate categories of psychedelic experiences were identified through data analysis: High scoring, Low scoring, and Positive scoring. 

In terms of the remission of anxiety and depressive symptoms as well as other longer-lasting advantages, those with the highest levels of mystical and insightful experiences and the lowest levels of hard experiences benefited the most.

(Source: https://theprint.in/health/low-estrogen-levels-paired-with-higher-cgrp-levels-may-jump-start-migraine-study/1394931/)